Bremelanotide
- Generic Name
- Bremelanotide
- Brand Names
- Vyleesi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 189691-06-3
- Unique Ingredient Identifier
- 6Y24O4F92S
- Background
Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women. Bremelanotide does not interact with alcohol. The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.
Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141. Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. Other drugs used to treat female sexual dysfunction include flibanserin, estrogen, ospemifene, and prasterone.
Bremelanotide was granted FDA approval on 21 June 2019.
- Indication
Bremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug.
- Associated Conditions
- Hypoactive Sexual Desire Disorder (HSDD)
- Associated Therapies
- -
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 108
- Registration Number
- NCT06565611
- Locations
- 🇺🇸
University Clinical Research-DeLand LLC, d/b/a Accel Research, DeLand, Florida, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸Coastal Carolina Research Center, North Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.